Long COVID Long COVID
Conditions
Interventions
Tsumura Hochuekkito Extract Granules 2.5 g or Placebo Granules 2.5 g should be administered orally three times daily before or between meals. Dosage and frequency of administration may be adjusted acc
Sponsors
Tokumasu Kazuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients with COVID-19 confirmed by PCR or other tests 2. outpatients (patients with mild COVID-19 disease) 3. patients with COVID-19 onset of more than 4 weeks but less than 24 weeks 4. those with a FAS (Fatigue Assessment Scale) score of 22 or more 5. who are able to complete the questionnaire online, e.g. by smartphone or computer 6. patients aged 18 years or older (regardless of sex) at the time consent is obtained 7. patients who have given a full explanation of their participation in the study, and who have given their free and voluntary written consent based on a full understanding of the study. For *1, 2 and 3, patients who have been affected by COVID-19 more than once, the criteria are for the COVID-19 in which the sequelae appeared.
Exclusion criteria
Exclusion criteria: 1. patients with any of the following diseases or laboratory abnormalities that cause general malaise on examination at the time of admission Active infectious diseases (active pulmonary tuberculosis, active infections such as hepatitis B and C viruses) Endocrine and metabolic disorders (adrenal insufficiency, thyroid dysfunction, poorly controlled diabetes (blood glucose level shows more than 300 mg/dL at any time)) Hypoglycemia (serum K = 3.2 mEq/L or less), hyponatremia (serum Na = 125mmol/L or less), hypernatraemia (serum Na = 150 mmol/L or less), hypercalcemia (corrected serum Ca = 12 mg/dL or more), Severe anemia (Hb 9g/dL or less: women, Hb10g/dL or less: men) 2. patients who have taken Kampo medicines within 1 week prior to study enrollment (or within 4 weeks prior to enrollment for Kampo medicines prescribed for fatigue or malaise*). *Hochuekkito, Juzentaihoto, Ninjin'yoeito, Kihito, Kamikihito, Seishoekkito, Hangebyakujutsutemmato, Daibofuto, Tokito, Seishinrenshiin, Shikunshito, Rikkunshito, Rokumigan, Hachimijiogan, Goshajinkigan, Shokenchuto, Ogikenchuto. 3. patients with a history of adverse reactions such as allergy to hochuekkiro 4. women who are pregnant or may become pregnant 5. patients with a history or comorbidities such as myalgic encephalomyelitis/chronic fatigue syndrome, fibromyalgia, rheumatic diseases, adrenal insufficiency or growth hormone deficiency that may cause chronic fatigue Note: The exclusion criteria shall not be applicable if it is determined that these diseases are not the primary cause of the fatigue at the time of the visit. 6. patients who, at the time of presentation, are attending a psychiatric department and are being treated for an ICD-10 (International Classification of Diseases) Chapter 5 mental and behavioural disorder (see separate document: ICD-10 (International Classification of Diseases) Chapter 5 Mental and Behavioural Disorders) 7. other patients who are judged to be inappropriate as research subjects by the principal investigator and the sub-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue Assessment Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Quality of life scale: Euro-QOL 2. Self-rating depression scale (SDS) 3. Anxiety scale: STAI from JYZ 4. Fatigue level assessed by performance status 5. Short Qi deficiency scale 6.Long COVID associated symptoms 7.Adverse events (side effects) attributable to Hochuekkito from the start of the intervention to 6 weeks post-intervention. | — |
Contacts
Public ContactKazuki Tokumasu
Okayama University Hospital
Outcome results
None listed